Literature DB >> 12388808

Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response.

S A Jeffs1, C Shotton2, P Balfe3, J A McKeating4.   

Abstract

Removal of the V1-V3 loops from IIIB gp120 results in a protein, PR12, with altered immunogenicity compared to the full-length protein. Polyclonal immune sera raised in rats using PR12 as immunogen recognizes envelope glycoproteins of clades A, B, C, E, F and G and can neutralize chimeric human immunodeficiency virus type 1 (HIV-1) HXB2 viruses expressing envelopes from primary HIV-1 clades B, C, E and F. These data suggest that the immune response to PR12 is directed toward conserved epitopes expressed by viral glycoproteins of diverse genotypes. Five monoclonal antibodies (mAb) derived from PR12-immunized rats were unable to neutralize virus infectivity; hence the epitopes responsible for the induction of this cross-clade neutralizing activity remain to be elucidated. However, PR12 immune sera were able to compete with the human neutralizing mAb 2G12 for gp120 binding, implying that this epitope may be immunogenic when expressed in the context of this truncated protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388808     DOI: 10.1099/0022-1317-83-11-2723

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

2.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 3.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

4.  Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Authors:  B Poon; J T Safrit; H McClure; C Kitchen; J F Hsu; V Gudeman; C Petropoulos; T Wrin; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Authors:  George Sellhorn; Zane Kraft; Zachary Caldwell; Katharine Ellingson; Christine Mineart; Michael S Seaman; David C Montefiori; Eliza Lagerquist; Leonidas Stamatatos
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

6.  Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.

Authors:  B Poon; J F Hsu; V Gudeman; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 7.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

8.  Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.

Authors:  Ilja Bontjer; Aafke Land; Dirk Eggink; Erwin Verkade; Kiki Tuin; Chris Baldwin; Georgios Pollakis; William A Paxton; Ineke Braakman; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

9.  Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Authors:  Mei-Yun Zhang; Xiaodong Xiao; Igor A Sidorov; Vidita Choudhry; Fatim Cham; Peng Fei Zhang; Peter Bouma; Michael Zwick; Anil Choudhary; David C Montefiori; Christopher C Broder; Dennis R Burton; Gerald V Quinnan; Dimiter S Dimitrov
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Glycosylation of immunodominant linear epitopes in the carboxy-terminal region of the caprine arthritis-encephalitis virus surface envelope enhances vaccine-induced type-specific and cross-reactive neutralizing antibody responses.

Authors:  J D Trujillo; N M Kumpula-McWhirter; K J Hötzel; M Gonzalez; W P Cheevers
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.